Dashboard
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 17.75
2
Healthy long term growth as Net Sales has grown by an annual rate of 18.37% and Operating profit at 12.36%
3
Positive results in Jun 25
4
With ROE of 6.69%, it has a expensive valuation with a 4.16 Price to Book Value
5
Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks
6
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
SEK 21,807 Million (Small Cap)
62.00
NA
0.41%
0.89
7.64%
4.11
Revenue and Profits:
Net Sales:
2,578 Million
(Quarterly Results - Jun 2025)
Net Profit:
100 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
22.92%
0%
22.92%
6 Months
29.72%
0%
29.72%
1 Year
51.28%
0%
51.28%
2 Years
35.58%
0%
35.58%
3 Years
-13.97%
0%
-13.97%
4 Years
-31.4%
0%
-31.4%
5 Years
122.7%
0%
122.7%
AddLife AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
18.37%
EBIT Growth (5y)
12.36%
EBIT to Interest (avg)
17.75
Debt to EBITDA (avg)
2.74
Net Debt to Equity (avg)
0.86
Sales to Capital Employed (avg)
0.96
Tax Ratio
34.80%
Dividend Payout Ratio
36.27%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
12.70%
ROE (avg)
13.77%
Valuation key factors
Factor
Value
P/E Ratio
62
Industry P/E
Price to Book Value
4.16
EV to EBIT
34.47
EV to EBITDA
16.78
EV to Capital Employed
2.66
EV to Sales
2.56
PEG Ratio
0.94
Dividend Yield
0.40%
ROCE (Latest)
7.71%
ROE (Latest)
6.69%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
2,578.00
2,702.00
-4.59%
Operating Profit (PBDIT) excl Other Income
392.00
441.00
-11.11%
Interest
54.00
63.00
-14.29%
Exceptional Items
0.00
-13.00
100.00%
Consolidate Net Profit
100.00
120.00
-16.67%
Operating Profit Margin (Excl OI)
74.10%
89.20%
-1.51%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -4.59% vs -4.12% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -16.67% vs 27.66% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
10,286.00
9,685.00
6.21%
Operating Profit (PBDIT) excl Other Income
1,532.00
1,458.00
5.08%
Interest
319.00
288.00
10.76%
Exceptional Items
-10.00
14.00
-171.43%
Consolidate Net Profit
254.00
192.00
32.29%
Operating Profit Margin (Excl OI)
70.00%
55.70%
1.43%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 6.21% vs 6.62% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 32.29% vs -60.25% in Dec 2023
About AddLife AB 
AddLife AB
Pharmaceuticals & Biotechnology
AddLife AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector. The Company operates through two segments: The LabTech segment is engaged in the sales of laboratory equipment, analytical instruments and reagents, that are used for diagnostics or biomedical research; The MedTech segment offers various medical device equipment, consumables, instruments and devices, primarily to hospitals. The Company operates through number of subsidiaries, such as BergmanLabora AB, BioNordica group, Holm & Halby A/S, Immuno Diagnostic Oy, LabRobot Products AB, Triolab-group, Active Care Sverup AB, Fenno Medical Oy, Mediplast AB, among others.
Company Coordinates 
Company Details
Brunkebergstorg 5, Box 3145 , STOCKHOLM None : 103 62
Registrar Details






